Navigation Links
ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
Date:1/26/2009

LEUVEN, Belgium and LUND, Sweden, January 26 /PRNewswire-FirstCall/ -- ThromboGenics NV (EURONEXT:THR) and BioInvent International AB (OMXS:BINV) announce today that they have received a technology transfer success fee of EUR5 million from Roche under the terms of their strategic alliance for the novel anti-cancer antibody, TB-403. The payment has been triggered by the successful transfer and implementation of technology and process development to Roche in relation to the ongoing clinical development of TB-403.

The TB-403 strategic alliance with Roche was signed in June 2008. Under the terms of this ongoing agreement, ThromboGenics and BioInvent received an initial upfront payment of EUR50 million, with the potential of milestone payments of up to EUR450 million following completion of a series of development and commercial milestones, as well as double digit royalties on future sales. ThromboGenics, which discovered TB-403, receives 60% and BioInvent 40% of the revenue from the deal.

Under the terms of the agreement, Roche is responsible for all development costs for TB-403, including the completion of the Phase Ib trial currently being run by BioInvent and ThromboGenics.

TB-403 (anti-PlGF) is a humanized monoclonal antibody that blocks the formation of the new blood vessels required by solid tumours to support growth. PlGF is a homologue of VEGF, and clinical evidence suggests that it plays a role in the angiogenesis of malignant tissue, and does not affect normal tissue angiogenesis.

Patrik De Haes, CEO of ThromboGenics, commented, "We are very pleased to be able to make this announcement today. The fact that we have been able to achieve the goal that has triggered this payment from Roche so quickly highlights the excellent working relationship that has developed between all parties in this important strategic alliance. We are looking forward to the results of the current Ph
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
2. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
3. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
4. PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in Expanded Indications
5. Kiadis Pharma Receives Two Orphan Drug Designations for Reviroc(TM) From the FDA
6. Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial
7. PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S.
8. Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union
9. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
10. Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors
11. Abbott Receives Complete Response Letter From FDA for Controlled-Release Hydrocodone With Acetaminophen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... The Open Paradigm Project, in collaboration ... Psychiatry , and leading organizations in the movement ... media campaign showcasing video testimonials by individuals negatively ... on pathology and illness rather than wellness and ... Association,s (APA) rollout of its latest revision of ...
(Date:5/17/2013)... , May 17, 2013  Lakeland Industries, Inc. (NASDAQ: ... protective clothing for industry, healthcare and to first responders ... its financial results for the fiscal 2013 fourth quarter ... 21, 2013 at stock market close and will conduct ... p.m. eastern. (Logo: http://photos.prnewswire.com/prnh/20120611/NY21959LOGO ) ...
(Date:5/17/2013)... 17, 2013   Shareholder rights attorneys  at Robbins ... Inc. (NASDAQGS: AVEO) securities has filed a complaint in ... Massachusetts .  The complaint alleges that Aveo ... Act of 1934 (the "Exchange Act") between January 3, ... (Logo: http://photos.prnewswire.com/prnh/20130103/MM36754LOGO ) ...
Breaking Medicine Technology:New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 2New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 3Lakeland Industries to Report Fiscal Fourth Quarter and Year End Financial Results and Conduct Conference Call 2Aveo Pharmaceuticals, Inc. Sued by Investor 2Aveo Pharmaceuticals, Inc. Sued by Investor 3
... N.C. , July 21 /PRNewswire-FirstCall / -- SPX ... completed the acquisition of the Anhydro business, a Soeborg, Denmark ... dewatering plants and equipment.  The terms of the transaction were not ... Anhydro ...
... DETROIT , July 21 Caraco Pharmaceutical ... shipping bupropion hydrochloride extended release tablets. This product was ... (FDA) for Sun Pharma,s Abbreviated New Drug Application (ANDA). ... mg, and 200 mg, are therapeutically equivalent to GlaxoSmithKline,s ...
Cached Medicine Technology:SPX Completes Acquisition of Anhydro 2SPX Completes Acquisition of Anhydro 3Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Wellbutrin SR® Extended Release Tablets 2
(Date:5/20/2013)... prepare for final exams, teens nationwide may be tempted ... or amphetamine -- to gain an academic edge. But ... in 100 parents of teens 13-17 years old believes ... drugs refer to stimulant medications typically prescribed for the ... medicines in this category include Adderall, Concerta, Ritalin, and ...
(Date:5/20/2013)... Join Seva Foundation in celebrating its 35th Anniversary ... of Fine Arts Theater in San Francisco, featuring: ... Shimshai, with host Wavy Gravy. All proceeds will benefit Seva ... Reserved seats are $40 & $55, VIP tickets are $150 ... front row seat at the show. Tickets are available through ...
(Date:5/20/2013)... A new Benefits of Pharmacy Home Delivery ... the MedEx Pack announced. The new report ... in order to provide useful details for those who are ... Furuta, MedEx Direct owner and pharmacist said, “One of the ... product like the MedEx Pack, patients can receive their own ...
(Date:5/20/2013)... research from the University of Southampton has shown that ... use echolocation, similar to that used by bats and ... The study, which is published in the journal ... hearing of echoes, could help blind people with spatial ... effects of hearing impairment and how to optimise echolocation ...
(Date:5/20/2013)... WEDI, the leading authority on the use ... information, announced today at the WEDI 22nd Annual National ... Collaborative Initiative. The new initiative will bring together state ... efficiencies and reduce the significant time and costs associated ... initiative is to help facilitate inter-state communication around ICD-10 ...
Breaking Medicine News(10 mins):Health News:1 in 10 teens using 'study drugs,' but parents aren't paying attention 2Health News:Memorial Day Kirtan Concert Palace of Fine Arts Theater in San Francisco Featuring: Snatam Kaur, Jai Uttal, C.C. White & Shimshai with host Wavy Gravy,May 27th 7:00 PM 2Health News:Benefits of Pharmacy Home Delivery Report Published by MedEx Direct 2Health News:New study finds blind people have the potential to use their 'inner bat' to locate objects 2Health News:WEDI Launches New ICD-10 State Collaborative Initiative to Increase Efficiencies and Reduce Compliance Time and Costs 2
... works, the greater his chances for high blood pressure, a new ... at the// University of California, Irvine analyzed more than 24,000 people ... found that people who worked 40 hours a week are 14 ... who work under 39 hours a week. Those who work 41 ...
... from Rensselaer Polytechnic Institute in Troy, N.Y., and the University ... the host receptors where anthrax toxin attaches in the body. ... bind to multiple sites on the host receptor making it ... site. The researchers found that the new approach led ...
... doctors were stranded for days at the Charity Hospital, when ... of the storm, Charles Gibson reports from that hospital. ... might think you're in a warehouse or some kind of ... ,Charity Hospital served the poor and uninsured people ...
... conjoined twins were separated after a lengthy surgery. 3 weeks ... to their father, it is an indication of their recovery., ... were conjoined at the trunk and shared several internal organs, ... various medical complications caused by the only kidney, the surgery ...
... draw a little closer in understanding the evolution of the ... be more infectious to people. ,According to ... influenza strains from the common human influenza. This conclusion follows ... type flu viruses. This analysis will also aid scientists trace ...
... the Northern Territory Government’s decision to fund rotavirus ... to follow suit and help// protect vulnerable children ... came after the Federal Government’s Pharmaceutical Benefits Advisory ... cost-effective to provide the rotavirus vaccine to all ...
Cached Medicine News:Health News:Inhibitor That Blocks Host Receptors Found To be Effective In Treating Anthrax 2Health News:Conjoined twins doing well after separation 2Health News:Understanding the Evolution of Viruses a little more Clearly 2
Freer elevator, double end, 7 1/4", S/B....
... The Surgifoam* absorbable gelatin sponge, ... porcine gelatin absorbable sponge intended for ... bleeding surface. The sponge is off-white ... and speed to hemostasis, highly favorable ...
... The Surgifoam* absorbable gelatin sponge, ... porcine gelatin absorbable sponge intended for ... bleeding surface. The sponge is off-white ... and speed to hemostasis, highly favorable ...
16 mm diameter curved probes with suture eyes just back of blunt ends. Stainless steel. Round knurled handle with polished finish. Overall length: 5.7 inches....
Medicine Products: